An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: The dust-raising effect

Journal of Neuroinflammation

Volumn 12, Issue 1, 2015, Pages

  Liu, Yu Hui ^a   Bu, Xian Le ^a   Liang, Chun Rong ^a   Wang, Ye Ran ^a   Zhang, Tao ^a   Jiao, Shu Sheng ^a   Zeng, Fan ^a   Yao, Xiu Qing ^a   Zhou, Hua Dong ^a   Deng, Juan ^a   Wang, Yan Jiang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer; Amyloid beta; Dust raising effect; Fibril; N terminal antibody; Oligomer

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; ANTIBODY; DIMER; N TERMINAL ANTIBODY 6E10; OLIGOMER; POLYMER; TRIMER; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CASPASE 3; ENOLASE; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DUST RAISING EFFECT; FEMALE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NERVOUS SYSTEM PARAMETERS; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN TARGETING; AMYLOID PLAQUE; ANALYSIS OF VARIANCE; ANIMAL; APOPTOSIS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; IMMUNOLOGY; METABOLISM; NEURITE; NEUROTOXICITY SYNDROMES; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY; TUNEL ASSAY; ULTRASTRUCTURE;

AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; APOPTOSIS; CASPASE 3; DISEASE MODELS, ANIMAL; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, TRANSMISSION; NEURITES; NEUROTOXICITY SYNDROMES; PEPTIDE FRAGMENTS; PHOSPHOPYRUVATE HYDRATASE; PLAQUE, AMYLOID;

EID: 84940173429     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-015-0379-4     Document Type: Article

References (31)

1. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10:698-712.
2. Boluda S, Toledo JB, Irwin DJ, Raible KM, Byrne MD, Lee EB, et al. A comparison of Abeta amyloid pathology staging systems and correlation with clinical diagnosis. Acta Neuropathol. 2014;128:543-50.
3. Lemere CA. Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013;8:36.
4. Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ. Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol. 2012;8:465-9.
5. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, et al. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006;169:1048-63.
6. Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, et al. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci. 2007;27:12721-31.
7. Zhao LN, Long H, Mu Y, Chew LY. The toxicity of amyloid beta oligomers. Int J Mol Sci. 2012;13:7303-27.
8. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology. 2005;64:129-31.
9. Ge JF, Qiao JP, Qi CC, Wang CW, Zhou JN. The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int. 2012;61:1192-201.
10. Ramakrishnan M, Kandimalla KK, Wengenack TM, Howell KG, Poduslo JF. Surface plasmon resonance binding kinetics of Alzheimer's disease amyloid beta peptide-capturing and plaque-binding monoclonal antibodies. Biochemistry. 2009;48:10405-15.
11. Wang YJ, Valadares D, Sun Y, Wang X, Zhong JH, Liu XH, et al. Effects of proNGF on neuronal viability, neurite growth and amyloid-beta metabolism. Neurotox Res. 2010;17:257-67.
12. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci U S A. 1997;94:4109-12.
13. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002;22:7873-8.
14. Hack PS CE. Intravenous immunoglobulins: a treatment for Alzheimer's disease? J Neurol Neurosurg Psychiatr. 2004;75:1374-5.
15. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation. 2010;7:90.
16. Wang YJ, Zhou HD, Zhou XF. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov Today. 2006;11:931-8.
17. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
18. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:311-21.
19. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008;372:216-23.
20. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002;1:3.
21. Mably AJ, Liu W, Mc Donald JM, Dodart JC, Bard F, Lemere CA, et al. Anti-Abeta antibodies incapable of reducing cerebral Abeta oligomers fail to attenuate spatial reference memory deficits in J20 mice. Neurobiol Dis. 2015;82:372-84.
22. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, et al. Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci. 2008;28:11950-8.
23. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837-42.
24. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563-72.
25. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25:629-36.
26. Deng J, Hou H, Giunta B, Mori T, Wang YJ, Fernandez F, et al. Autoreactive-Abeta antibodies promote APP beta-secretase processing. J Neurochem. 2012;120:732-40.
27. Li S, Deng J, Hou H, Tian J, Giunta B, Wang Y, et al. Specific antibody binding to the APP672-699 region shifts APP processing from alpha- to beta-cleavage. Cell Death Dis. 2014;5:e1374.
28. Colletier JP, Laganowsky A, Landau M, Zhao M, Soriaga AB, Goldschmidt L, et al. Molecular basis for amyloid-beta polymorphism. Proc Natl Acad Sci U S A. 2011;108:16938-43.
29. Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, et al. Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015.
30. Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T. Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol. 2004;335:997-1006.
31. Millucci L, Ghezzi L, Bernardini G, Santucci A. Conformations and biological activities of amyloid beta peptide 25-35. Curr Protein Pept Sci. 2010;11:54-67.